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Traditionally, operable breast cancer has been treated by primary 
surgery followed by adjuvant chemotherapy, radiotherapy, endocrine 
and targeted therapy as indicated. Primary systemic chemotherapy, 
more commonly known as neoadjuvant chemotherapy (NACT), 
was reserved for large inoperable tumours or for inflammatory 
breast cancer. Our current decisions on local therapy remain 
based on historical data, where surgery was the primary treatment 
modality. 
The extent of surgery in the treatment of breast cancer has dramat-
ically decreased following a surgical paradigm shift from maximum 
tolerated therapy towards minimum required therapy.[1] These shifts 
include the transition from routine axillary lymph node dissection 
(ALND) to sentinel lymph node biopsy (SLNB) in node-negative 
patients, and the transition from routine mastectomy to breast-con-
serving therapy. Conversely, the use of NACT in early breast cancer 
has increased dramatically over the past decade. This trend poses new 
challenges in the management of patients with early breast cancer, 
specifically with regard to decision-making on the management of 
the axilla and adjuvant radiation. 
Although endocrine therapy has a well-established role in the 
neoadjuvant setting, this review is confined to the use of NACT.
NACT in early breast cancer has no proven survival benefit,[2] but 
has other potential advantages:
• It allows assessment of the success of systemic therapy by 
monitoring the clinical and radiological responses.
• Tumour size and node involvement are reduced.[3]
• Breast conservation rates increase by 10 - 30%.[3-6]
• A pathological complete response (pCR) is a significant prognostic 
factor.[7]
• A large proportion of patients in Europe and the USA are enrolled 
in clinical trials, which allows an evaluation of response to therapy.
• It allows more axilla-preserving surgery.
The use of systemic therapy as the primary treatment modality also 
fits into the modern perception of breast cancer as a systemic disease.[8,9] 
It is well recognised that tumour behaviour is different in each patient 
and tumour biology has superseded the traditional approach of 
anatomical staging in treatment decisions. Furthermore, the primary 
tumour has a different biological behaviour compared with the more 
indolent lymph nodes. Lymph nodes are better thought of as being 
‘indicators but not governors of survival’.[10]
Response of axillary nodes to NACT
Nodal response to NACT is an important prognostic marker and 
patients who achieve a pCR have improved overall survival and 
disease-free survival.[7,11] Several studies have evaluated the response 
of positive axillary nodes to NACT (Table 1). 
Response rates vary according to tumour biology. Hormone 
receptor-positive patients are less likely to achieve pCR than those 
with triple-negative or human epidermal growth factor receptor 2 
(HER2)-positive breast cancer, highlighting the importance of patient 
selection.[15,16] With the addition of targeted therapy in HER2-positive 
patients, the conversion rates have increased to >70%.[18]
Besides the prognostic implications of evaluating response, the 
use of NACT has the attractive potential to increase axilla-preserving 
surgical therapy by reducing the need for ALND in patients who are 
node-negative after NACT.
Although removal of the lymph nodes may have little impact on 
survival, it adds to local control. In early breast cancer, lymph node 
status remains one of the most important prognostic factors and 
it is imperative to accurately stage all patients prior to starting any 
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Table 1. Summation of principal studies on nodal response to 
NACT
Study Nodal pCR, n (%)
Koolen et al.[12] 80 (40.0)
Park et al.[13] 178 (41.0)
Hieken et al.[14] 272 (38.5)
Boughey et al.[15] 649 (41.0)
Mamtani et al.[16] 195 (49.0)
Alvarado et al.[17] 150 (42.0)
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therapy, including NACT. Therefore, all patients require a clinical and 
sonographic assessment of the axilla.
After assessment, patients fall into two groups:
• Clinically node-negative (cN0) patients, with no sign of regional 
metastases on clinical examination and imaging.
• Clinically node-positive (N1) patients, with signs of regional metastases 
on clinical examination and/or imaging, which must be proven by fine 
needle aspiration (FNA) or core biopsy of the nodes.
The first group all require SLNB (ALND for node-negative patients 
has become obsolete in contemporary breast cancer surgery). The 
considerations are:
• the timing of the procedure – should it be performed before or 
after NACT?
• whether a patient who had a positive SLNB prior to NACT could 
have a repeat SLNB after NACT to increase the rate of axillary 
preservation?
The second group of patients may continue to be node-positive 
after NACT or may convert to node-negative. Patients who present 
with nodal involvement and have persistent nodal involvement after 
NACT should all have ALND; there is no role for SLNB. However, 
if patients convert to a clinically node-negative state, can one safely 
perform an SLNB and preserve the axilla? 
Clinically node-negative patients prior 
to NACT
Accuracy of SLNB after NACT 
Data on accuracy and safety of SLNB were based on patients who had 
surgery first. Therefore, there were initial major concerns about the 
false-negative rate (FNR) and the feasibility and reliability of SLNB 
after NACT. However, Hunt et al.[19] compared the accuracy of SLNB 
in 575 patients after NACT with 3 746 patients undergoing primary 
SLNB, which showed comparable results. The safety of the procedure 
after NACT was confirmed by various other studies and two meta-
analyses.[20,21] The National Comprehensive Cancer Network (NCCN) 
guidelines allow SLNB both before and after NACT.[22]
Timing of SLNB
SLNB before NACT – the ‘up-front’ procedure
SLNB prior to NACT reflects the ‘true’ stage of the patient and allows 
accurate prognostication. Proponents for the up-front procedure 
have argued that a positive node may indicate the use of NACT; in the 
authors’ experience this is uncommon and the indication for NACT 
is made most often by consideration of tumour biology. The ratio of 
the primary lesion to the breast size may also be an indication for 
primary systemic therapy. In some cases, though, a single positive 
node will indicate the use of radiotherapy after a mastectomy. 
This can be extremely important information in the planning of 
reconstructive approaches.
If the sentinel node is free of disease, no further surgical 
management of the axilla is required. If the node is involved, should 
the patient have an ALND at the time of definitive surgery or a second 
SLNB? This question was answered by the SENTinel  NeoAdjuvant 
(SENTINA) trial.[23] Clinically node-negative patients with a positive 
SLNB prior to NACT underwent a second SLNB after chemotherapy. 
The identification rate (IR) was 61.0% and the FNR 51.6%. The trial 
showed clearly that a second SLNB after NACT is not plausible. 
From a clinical perspective this is important; when we decide on an 
up-front SLNB, we deny more patients the opportunity of NACT 
converting them to node-negative status and preserving the axilla. 
When the SLNB is positive, we are committed to an ALND. In 
general, a patient who has an up-front SLNB will always require a 
second operation, regardless of nodal status.
SLNB after NACT 
This approach allows a greater rate of minimal axillary surgery, given 
that many patients will convert to node-negative (Table 2).[19] 
If the sentinel node is negative, no further surgical management 
is required and the patient is spared the morbidity of an ALND. 
Furthermore, the patient is spared a second operation with an 
up-front SLNB. However, a negative SLNB after NACT can create 
uncertainty regarding the need of adjuvant radiation. 
If the nodes are found to be involved, the patient should undergo 
ALND.
Clinically node-positive patients prior 
to NACT
The traditional approach has been that anyone with treatable breast 
cancer and a positive axillary node should have an ALND. This 
approach is undoubtedly correct if the patient remains clinically 
node-positive after NACT. Given the high rates of pCR following 
NACT, is ALND still necessary in patients who convert to node-
negative? 
Restaging the axilla with ultrasound scanning, magnetic resonance 
imaging (MRI) or positron emission tomography (PET) remains 
inadequate in predicting pathological response; histology is then 
mandatory. The data from retrospective studies attempting SLNB 
in patients who converted to clinically node-negative after NACT 
showed unacceptably high FNRs.[17,24,25] However, the results from 
three multicentre prospective trials suggest that SLNB in this 
subgroup of patients may be acceptable.
The SENTINA trial[23] divided 2 234 patients who received NACT 
into four groups. One of these groups comprised clinically node-
positive patients who became clinically node-negative after NACT. 
They had an SLNB and completion ALND; the IR was 80.0% and the 
FNR 14.2%, exceeding the acceptable FNR of 10.0%. A very important 
finding was that the FNR reduced to ˂10% if ≥3 nodes were removed. 
The results also highlighted the benefit of a dual-tracer technique 
(patent blue and technetium-99m (99mTc)-nanocolloid) in this setting. 
The American College of Surgeons Oncology Group (ACOSOG) 
Z-1071 trial investigated 649 patients who underwent SLNB and 
ALND after NACT, regardless of their clinical node status.[15] The 
FNR was 12.6% but the FNR again decreased to 9.1%, with dual-
tracer technique and removal of ≥3 nodes. However, the trial was 
considered to have failed as the threshold of acceptable FNR (<10%) 
was not achieved. A major shortcoming of the trial was the inclusion 
of patients without a complete clinical and radiological response.
In the Sentinel Node Biopsy Following NeoAdjuvant Chemo-
therapy in Biopsy Proven Node Positive Breast Cancer (SN-FNAC) 
trial,[26] a dual tracer technique was used to locate sentinel lymph 
nodes in 153 patients who were node-negative after NACT. Metastases 
Table 2. Identification rate, false-negative rate and local 
regional recurrence rate following SLNB before and after 
NACT[19]
Primary SLNB, %  
(n=3 746)





IR = identification rate; FNR = false-negative rate; LLR = local regional recurrence rate.
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of any size were considered to be relevant 
and achieved an identification rate of 87.6%. 
The FNR was 4.9% with ≥2 sentinel nodes. 
In this trial the importance of using a dual 
tracer was emphasised. Use of immunohis-
tochemistry to identify micrometastases and 
isolated tumour cells also reduced the FNR; 
the size of all metastases should be consid-
ered significant after NACT.
Although these trials pointed out the 
potential to reduce ALND in node-positive 
patients, there were still major concerns 
regarding the number of patients in whom 
this would be applicable.[27] Importantly, the 
removed nodes must be true sentinel nodes, 
i.e. hot and/or blue nodes, and must not be 
randomly sampled. Mamtani et al.[16] investi-
gated patients with histologically proven 
node-positive disease who underwent 
NACT; 68.0% turned clinically node-nega-
tive and were eligible for SLNB. Of 128 SLNB 
attempts, ≥3 sentinels were identified in 86.0%, 
and 48.0% were histologically node-negative 
and spared an ALND. This study and a 
recent meta-analysis[28] emphasise the major 
role of NACT to reduce ALND in patients 
with initial nodal disease and the feasibility 
of the procedure. 
It must be pointed out that we lack long-
term data on locoregional recurrence and 
survival in patients who had an SLNB only 
after converting from node-positive to node-
negative with NACT. Despite this, the current 
NCCN guidelines now allow for both ALND 
and SLNB in this patient group.[22]
In a further attempt to decrease the FNR, 
clipping of involved nodes to guide removal 
after NACT has been proposed.[29,30] Given 
the increased cost and complexity of this 
approach, the clinical application in our 
setting is questionable.
In Fig. 1 the recommendations are sum-
marised with regard to the timing of SLNB 
when NACT is given.
Conclusion
NACT has major potential to decrease the 
extent of surgery performed in the axilla.
If the nodal status is negative prior to 
starting NACT, it is safe to do an SLNB 
after NACT. If a node-positive patient has 
evidence of axillary disease after NACT, they 
should have an ALND. Patients who convert 
from node-positive to node-negative can 
have an SLNB, but:
• at least three nodes should be removed
• both patent blue and 99mTc-nanocolloid 
should be used to identify the nodes
• any size of lymph node metastasis should 
be considered to be node-positive and 
should prompt ALND.
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